TLDR
- Shares of Immutep plummeted approximately 80% on Friday following the termination of its Phase III lung cancer study due to futility concerns.
- An Independent Data Monitoring Committee advised terminating the TACTI-004 trial, which was testing eftilagimod alfa (efti) for first-line non-small cell lung cancer treatment.
- Baird analysts cut their rating from Outperform to Neutral while reducing the price target dramatically from $7.00 down to $1.00.
- Citizens similarly downgraded IMMP from Market Outperform to Market Perform, eliminating all NSCLC-related revenue forecasts from their model.
- Share volume surged past 11 million trades — a dramatic increase from the typical daily average of approximately 154,000 — as shareholders rapidly exited positions.
Immutep (IMMP) experienced a devastating 80% decline on Friday following the biotechnology company’s announcement that it would discontinue its TACTI-004 Phase III clinical study. The trial was investigating eftilagimod alfa, referred to as “efti,” as a treatment option for patients diagnosed with first-line non-small cell lung cancer (NSCLC).
The termination came after the Independent Data Monitoring Committee (IDMC) conducted a thorough review of both safety and efficacy information, ultimately determining the trial should cease due to futility. Simply put: the available evidence indicated the therapy was unlikely to achieve its intended objectives even if the study were to continue.
Chief Executive Marc Voigt expressed clear disappointment with the findings. “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” he stated publicly.
The company confirmed it will immediately stop enrolling new participants and initiate a systematic shutdown of the study, which includes conducting patient follow-up procedures and closing study sites according to regulatory standards.
Analysts Cut Ratings and Price Targets
Wall Street’s response came quickly and decisively.
Baird’s Colleen Kusy moved her rating from Outperform to Neutral while dramatically slashing her price target from $7.00 to just $1.00. At the time of the downgrade, shares were trading near $2.76, meaning they were still above even that reduced target. Baird’s analysis concluded there isn’t a viable pathway forward for efti based on these trial results.
Citizens analyst Reni Benjamin followed suit, downgrading the stock from Market Outperform to Market Perform. Benjamin completely eliminated revenue projections associated with the NSCLC indication from future earnings models.
Both research firms anticipate the stock will perform in line with broader market trends until substantive data emerges from the company’s other randomized clinical studies.
Prior to Friday’s collapse, IMMP stock was down roughly 3.5% for the year-to-date period, though it had gained 55% over the trailing twelve months. That annual gain has now been virtually eliminated.
What Happens Next for Immutep
There is one potential positive development for the company: with the TACTI-004 study being terminated, Immutep will no longer incur those substantial trial expenses. As a result, the company anticipates its cash reserves will last significantly longer than the previously projected Q2 2027 runway. Management stated it will provide revised cash guidance once the trial shutdown process is complete.
The company emphasized it will maintain focus on advancing other pipeline programs. That said, given that NSCLC represented the flagship development program, the company’s strategic options appear notably more limited.
Trading activity on Friday painted a vivid picture of investor sentiment. Over 11 million shares were traded during the morning session alone — a stark contrast to the three-month daily average volume of roughly 154,000 shares. This represents approximately 70 times the typical trading activity.
The current consensus rating on IMMP stands at Hold, derived from two Hold ratings. No average price target is available for the stock at this time.
